Breast Cancer
Conditions
Brief summary
This is a Phase III, double-blind, randomized multicenter study to compare the efficacy and to evaluate the safety and immunogenicity of HLX02 and European Union (EU)-sourced Herceptin® in patients with human epidermal growth factor receptor 2 (HER2)-positive, locally recurrent or previously untreated metastatic breast cancer.
Detailed description
This is a Phase III, double-blind, randomized multicenter study to compare the efficacy and to evaluate the safety and immunogenicity of HLX02 and European Union (EU)-sourced Herceptin® in patients with human epidermal growth factor receptor 2 (HER2)-positive, recurrent or previously untreated metastatic breast cancer. Eligible patients will be assessed centrally for HER2 status and the presence of at least one measurable target lesion before randomization. Patients will undergo a tumor assessment for evaluation of response according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) every 6 weeks up to 24 weeks (regardless of the number of cycles actually given); thereafter, assessments will be done every 9 weeks (after Cycles 11, 14, and 17) or earlier in the case of clinical signs of progression.
Interventions
BIOLOGICALHLX02
8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles.
BIOLOGICALHerceptin®
8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles
DRUGdocetaxel
75 mg/m2 will be administered on Day 2, Cycle 1.then be given every 3 weeks on Day 1 of each subsequent cycle
Sponsors
Shanghai Henlius Biotech
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients have voluntarily agreed to participate and given written informed consent. * Male or female ≥18 years of age on day of signing the informed consent form (ICF). * Histologically or cytologically confirmed adenocarcinoma of the breast. * Recurrent disease not amenable to curative surgery or radiation therapy, or metastatic disease with an indication for a taxane-containing therapy. * Availability of formalin-fixed paraffin-embedded (FFPE) tissue block from the primary tumor, or a metastatic lesion, to confirm HER2-positivity by the central laboratory, based on FISH amplification ratio ≥2.0 or IHC score 3+, and for hormone status (ER/PgR) determination (local or central laboratory). If not possible, a fresh biopsy is required. * No prior systemic anticancer agent such as chemotherapy, biological or targeted agent for metastatic disease with the exception of hormonal therapy, which must be stopped at least 2 weeks before randomization. Use of herbal remedies or traditional Chinese medicines for anticancer, hematologic or liver function, or anti-infective treatment must be stopped at the time of the ICF signature (at least 2 weeks before randomization). * For patients with recurrent disease, prior neo-/adjuvant therapy containing trastuzumab and/or lapatinib must have been stopped at least 12 months before the diagnosis of recurrent (local or metastatic) disease. If trastuzumab/lapatinib was not used, prior neo-/adjuvant therapy with a taxane must have been stopped at least 6 months before the diagnosis of recurrent (local or metastatic) disease. If only other cytotoxics were given, they must be stopped at least 4 weeks before randomization. Any hormonal therapy must be stopped at the time of the ICF signature. * Measurable disease (at least one measurable target lesion assessed by CIR; bone-only or central nervous system \[CNS\]-only metastases are not allowed). * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. * LVEF within institutional range of normal at baseline (within 42 days before randomization) as determined by either echocardiography (ECHO) or multigated acquisition (MUGA) scan. * Adequate hematologic, hepatic and renal function as indicated by the following laboratory values: * Absolute neutrophil count (ANC) ≥1,500/μL without granulocyte-colony stimulating factor (G-CSF) or other medical support * Platelets ≥100,000/μL * Hemoglobin ≥9 g/dL without transfusion or other medical support within 14 days * Serum creatinine ≤1.5 x upper limit of normal (ULN) and creatinine clearance rate ≥50 mL/min, calculated according to Cockroft-Gault formula * Serum total bilirubin ≤1.5 x ULN (unless the patient has documented ·Gilbert's syndrome) without any medical support within 14 days * Serum aspartate aminotransferase/glutamicoxaloacetic transaminase (AST/SGOT) or serum alanine aminotransferase/glutamate-pyruvate transaminase (ALT/SGPT) ≤2.5 x ULN (≤5 x ULN in the case of liver metastases) provided alkaline phosphatase (ALK) is ≤2.5 x ULN. In the case of bone metastasis, serum ALK can be \>2.5 x ULN if AST and ALT are ≤1.5 x ULN without any medical support within 14 days * International normalized ratio (INR), and activated partial prothrombin time (aPTT) or partial prothrombin time (PTT) ≤1.5 x ULN. * Estimated life expectancy ≥3 months. * Female patients are eligible to enter and participate in the study if they are of: Non-childbearing potential. Childbearing potential, have a negative serum pregnancy test at Screening, are not breast feeding, and use highly-effective or acceptable contraceptive measures before study entry and throughout the study until 7 months after the last investigational/comparator product administration. Highly-effective or acceptable contraceptive measures. * Male patients with partners of childbearing potential are eligible to enter and participate in the study if they, and their female partners, are willing to use highly-effective or acceptable contraceptive measures before study entry and throughout the study until 7 months after the last investigational/comparator product administration.
Exclusion criteria
* Previously- or currently-treated (systemic chemotherapy, biological, or targeted agent, or any other anticancer agent) metastatic breast cancer with the exception of hormonal therapy. * Known brain metastasis or other CNS metastasis that is either symptomatic or untreated. Central nervous system metastases that have been treated by complete resection and/or radiotherapy demonstrating stability or improvement are not an exclusion criterion provided they are stable as shown by computed tomography (CT) scan for at least 4 weeks before Screening without evidence of cerebral edema and no requirements for corticosteroids or anticonvulsants. * Participation in another clinical study within 4 weeks before enrollment (3 months for studies involving monoclonal therapy) or the intention of participating in another clinical study during any part of the study period. * History of other malignancy within the last 5 years, except for carcinoma in-situ of the cervix, basal cell carcinoma or squamous cell carcinoma of the skin that has been previously treated with curative intent. * Known history of human immunodeficiency virus (HIV). Clinically significant active infection requiring therapy; positive tests for hepatitis B; or hepatitis C. * Underlying medical conditions or current severe, uncontrolled systemic disease that, in the Investigator's opinion, will make the administration of study drug hazardous. A major surgical procedure within 4 weeks prior to enrollment or anticipation of the need for major surgery during the course of study. * Current uncontrolled hypertension (systolic \>150 mmHg and/or diastolic \>100 mmHg) or unstable angina. * History of chronic heart failure based on any New York Heart Association (NYHA) criteria, or left ventricular hypertrophy. Current serious cardiac arrhythmia requiring treatment or clinically significant conduction defects as seen on electrocardiogram (ECG). History of myocardial infarction within 6 months of randomization. History of LVEF decline to below 50% during or after previous trastuzumab neo-adjuvant or adjuvant therapy. Significant cardiac murmurs either on examination or ECHO. * History of prior exposure to doxorubicin \>360 mg/m² (or equivalent). Use of oral, injected or implanted hormonal methods of contraception. Chronic daily use of corticoids (equivalent to \>10 mg/day methylprednisolone) by oral intake (inhalation is permitted). * Known hypersensitivity to any of the study drugs. * Residual non-hematologic toxicity ≥ Grade 2 from prior therapy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ORR 24 | From time of First treatment to week 24 | calculated as the proportion of patients with a best response of complete response (CR) or partial response (PR) from first assessment until Week 24 according to RECIST 1.1 by central imaging review (CIR). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions,Complete Response (CR): Disappearance of all target lesions.Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to\<10 mm, Partial Response (PR): At least a 30% decrease in the sum ofdiameters of target lesions, taking as reference thebaseline sum diameters.Overall Response (OR) = CR + PR. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| DoR | Up to 2 years | The time from first documentation of CR or PR to the first documentation of progression. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1)，At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm or Unequivocal progression of existing non-target lesions (Note: the appearance of one or more new lesions is also considered progression). |
| DCR | Up to 2 years | The percentage of patients who achieve CR, PR, or stable disease (SD) of at least 12 weeks |
| CBR | Up to 2 years | The proportion of patients who achieve CR, PR, or durable SD (SD ≥24 weeks) |
| Median PFS up to 12 Months | From time of first treatment to 12 months | Median Progression Survival time assessed at 12 months.The probability of being alive without documented progression up to 12 months after randomization. |
| Overall Survival at 12, 24, and 36 Months | From time of first treatment to 36 months | the probability of being alive 12, 24, and 36 months after randomization |
Countries
China, Philippines, Ukraine
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| HLX02+Docetaxel HLX02: 8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles for up to a maximum of 12 months.
Docetaxel: 75 mg/m2 will be administered on Day 2, Cycle 1.then be given every 3 weeks on Day 1 of each subsequent cycle e for at least 8 cycles (until Week 24) and thereafter at the Investigator's discretion for up to a maximum of 12 months. | 325 |
| Herceptin®+Docetaxel Herceptin®: 8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles for up to a maximum of 12 months.
Docetaxel: 75 mg/m2 will be administered on Day 2, Cycle 1.then be given every 3 weeks on Day 1 of each subsequent cycle for at least 8 cycles (until Week 24) and thereafter at the Investigator's discretion for up to a maximum of 12 months. | 327 |
| Total | 652 |
Baseline characteristics
| Characteristic | Total | Herceptin®+Docetaxel | HLX02+Docetaxel |
|---|---|---|---|
| Age, Continuous | 54 years | 53 years | 54 years |
| ECOG performance status 0(Fully active, able to carry on all pre-disease performance without restriction) | 277 Participants | 139 Participants | 138 Participants |
| ECOG performance status 1(Restricted in physically strenuous activity but ambulatory and able to carry out light work ) | 372 Participants | 186 Participants | 186 Participants |
| ECOG performance status Missing | 3 Participants | 2 Participants | 1 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 501 Participants | 252 Participants | 249 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 151 Participants | 75 Participants | 76 Participants |
| Region of Enrollment China | 475 participants | 237 participants | 238 participants |
| Region of Enrollment Philippines | 26 participants | 15 participants | 11 participants |
| Region of Enrollment Ukraine | 151 participants | 75 participants | 76 participants |
| Sex: Female, Male Female | 652 Participants | 327 Participants | 325 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 128 / 325 | 142 / 327 |
| other Total, other adverse events | 320 / 325 | 321 / 327 |
| serious Total, serious adverse events | 78 / 325 | 81 / 327 |
Outcome results
Primary
ORR 24
calculated as the proportion of patients with a best response of complete response (CR) or partial response (PR) from first assessment until Week 24 according to RECIST 1.1 by central imaging review (CIR). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions,Complete Response (CR): Disappearance of all target lesions.Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to\<10 mm, Partial Response (PR): At least a 30% decrease in the sum ofdiameters of target lesions, taking as reference thebaseline sum diameters.Overall Response (OR) = CR + PR.
Time frame: From time of First treatment to week 24
Population: ITT set
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| HLX02+Docetaxel | ORR 24 | 71.1 percentage of responders |
| Herceptin®+Docetaxel | ORR 24 | 70.9 percentage of responders |
Secondary
CBR
The proportion of patients who achieve CR, PR, or durable SD (SD ≥24 weeks)
Time frame: Up to 2 years
Population: ITT set
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| HLX02+Docetaxel | CBR | 80.9 Clinical Benefit Rate(%) |
| Herceptin®+Docetaxel | CBR | 80.4 Clinical Benefit Rate(%) |
Secondary
DCR
The percentage of patients who achieve CR, PR, or stable disease (SD) of at least 12 weeks
Time frame: Up to 2 years
Population: ITT set
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| HLX02+Docetaxel | DCR | 84.3 percentage of participants |
| Herceptin®+Docetaxel | DCR | 87.2 percentage of participants |
Secondary
DoR
The time from first documentation of CR or PR to the first documentation of progression. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1)，At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm or Unequivocal progression of existing non-target lesions (Note: the appearance of one or more new lesions is also considered progression).
Time frame: Up to 2 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| HLX02+Docetaxel | DoR | 10.61 months |
| Herceptin®+Docetaxel | DoR | 10.25 months |
Secondary
Median PFS up to 12 Months
Median Progression Survival time assessed at 12 months.The probability of being alive without documented progression up to 12 months after randomization.
Time frame: From time of first treatment to 12 months
Population: ITT set
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| HLX02+Docetaxel | Median PFS up to 12 Months | 11.73 months |
| Herceptin®+Docetaxel | Median PFS up to 12 Months | 10.55 months |
Secondary
Overall Survival at 12, 24, and 36 Months
the probability of being alive 12, 24, and 36 months after randomization
Time frame: From time of first treatment to 36 months
Population: ITT set
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| HLX02+Docetaxel | Overall Survival at 12, 24, and 36 Months | 12 months (%) | 88.9 percentage of participants with OS |
| HLX02+Docetaxel | Overall Survival at 12, 24, and 36 Months | 24 months (%) | 71.4 percentage of participants with OS |
| HLX02+Docetaxel | Overall Survival at 12, 24, and 36 Months | 36 months (%) | 57.5 percentage of participants with OS |
| Herceptin®+Docetaxel | Overall Survival at 12, 24, and 36 Months | 12 months (%) | 88.4 percentage of participants with OS |
| Herceptin®+Docetaxel | Overall Survival at 12, 24, and 36 Months | 24 months (%) | 67.6 percentage of participants with OS |
| Herceptin®+Docetaxel | Overall Survival at 12, 24, and 36 Months | 36 months (%) | 54.0 percentage of participants with OS |